Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

F-031

Supelco

Fluconazol -Lösung

2.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C13H12F2N6O
CAS-Nummer:
86386-73-4
Molekulargewicht:
306.27
EG-Nummer:
200-659-6
MDL-Nummer:
MFCD00274549
UNSPSC-Code:
41116107
PubChem Substanz-ID:
329799654
NACRES:
NA.24

Qualität

certified reference material

Qualitätsniveau

300

Form

liquid

Leistungsmerkmale

(Snap-N-Spike®)

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

Konzentration

2.0 mg/mL in methanol

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

clinical testing

Format

single component solution

Lagertemp.

−20°C

SMILES String

Fc1c(ccc(c1)F)C(O)(C[n]3ncnc3)C[n]2ncnc2

InChI

1S/C13H12F2N6O/c14-10-1-2-11(12(15)3-10)13(22,4-20-8-16-6-18-20)5-21-9-17-7-19-21/h1-3,6-9,22H,4-5H2

InChIKey

RFHAOTPXVQNOHP-UHFFFAOYSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Verwandte Kategorien

Allgemeine Beschreibung

Fluconazole, sold under trade names such as Trican, Monicure, Diflucan®, and Afungil, is an antifungal drug used in the treatment and prevention of superficial and systemic fungal infections. This Certified Spiking Solution® is suitable as starting material for calibrators, controls, or linearity standards for therapeutic drug monitoring or clinical and diagnostic testing of fluconazole in patient blood, serum, or plasma samples by HPLC or LC-MS/MS.

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Diflucan is a registered trademark of Pfizer, Inc.
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Zielorgane

Eyes,Central nervous system

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 2

Flammpunkt (°F)

49.5 °F - closed cup

Flammpunkt (°C)

9.7 °C - closed cup

Zulassungslistungen

Zulassungslistungen werden hauptsächlich für chemische Produkte erstellt. Für nicht-chemische Produkte können hier nur begrenzte Angaben gemacht werden. Kein Eintrag bedeutet, dass keine der Komponenten gelistet ist. Es liegt in der Verantwortung des Benutzers, die sichere und legale Verwendung des Produkts zu gewährleisten.

EU REACH Annex XVII (Restriction List)

CAS No.

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Maria I Rosa et al.
European journal of obstetrics, gynecology, and reproductive biology, 167(2), 132-136 (2013-01-03)
To investigate the efficacy, compared to placebo, of fluconazole 150 mg weekly, given for six months as prophylaxis against recurrent vulvovaginal candidiasis (RVVC). A quantitative systematic review was performed, and randomized controlled trials were included. We conducted searches at Medline
Theodoros Kelesidis et al.
Scandinavian journal of infectious diseases, 42(1), 12-21 (2010-01-09)
The increasing numbers of joint arthroplasties being undertaken, and the increase in patients with systemic illnesses undergoing the procedure, have contributed to a continuing increase in prosthetic joint infections. Candida prosthetic joint infection is a rare clinical entity, and only
M C Ethier et al.
British journal of cancer, 106(10), 1626-1637 (2012-05-10)
Objectives were to compare systemic mould-active vs fluconazole prophylaxis in cancer patients receiving chemotherapy or haematopoietic stem cell transplantation (HSCT). We searched OVID MEDLINE and the Cochrane Central Register of Controlled Trials (1948-August 2011) and EMBASE (1980-August 2011). Randomised controlled
Jenny Wan Sai Cheong et al.
Medical mycology, 51(3), 261-269 (2012-09-20)
With the widespread use of long-term fluconazole prophylaxis and suppressive treatment, the potential development of fluconazole resistance poses a threat to the management of cryptococcal disease. Interpretive breakpoints for the in vitro antifungal susceptibility testing of C. neoformans have not
K Turner et al.
Current medicinal chemistry, 19(27), 4617-4620 (2012-08-11)
Invasive candidiasis (IC) in the premature infant population is a common infection that results in substantial morbidity and mortality. For these patients, fluconazole is among the first line therapies to treat and prevent IC, and yet few prospective studies investigating
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.